BTIG Starts Merrimack Pharmaceuticals (MACK) at Neutral
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
BTIG initiated coverage on Merrimack Pharmaceuticals (NASDAQ: MACK) with a Neutral rating.
Analyst Ling Wang said, "MACK’s lead compound, ONIVYDE, was approved in the US in post-gemcitabine metastatic pancreatic cancer. While we see ONIVYDE as having paradigm shift potential and significant expansion opportunities, we expect the sales ramp-up to be gradual in the current indication. Although MACK has strong fundamentals, with major data from ONIVYDE in front-line pancreatic cancer, MM-302 and MM-121 won’t be available until 2017 or beyond; we expect MACK shares to be range-bound."
Shares of Merrimack Pharmaceuticals closed at $5.01 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BTIG Raises Price Target on CardConnect Corp. (CCN) to $17; Reiterates Buy
- Aegis Capital Starts Cabot Microelectronics (CCMP) at Hold
- Mizuho Comments On Possible Toshiba Spinoff, Potential Futher Investment From Western Digital (WDC)
Create E-mail Alert Related CategoriesAnalyst Comments, New Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!